


WHAT IS CLAIMED IS:

1. Use of a combination of compounds for treating a disease or condition, wherein the combination includes an effective amount of Compound (A) and an effective amount of one or more of Compound (B), or a pharmaceutically acceptable salt thereof, wherein:

the Compound (A) has the structure:



wherein:

R^1 is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted C_1 - C_6 alkyl, a substituted or unsubstituted C_1 - C_6 haloalkyl, a substituted or unsubstituted C_3 - C_6 cycloalkyl, a substituted or unsubstituted C_1 - C_6 alkoxy, an unsubstituted mono- C_1 - C_6 alkylamine and an unsubstituted di- C_1 - C_6 alkylamine;

each R^2 is independently selected from the group consisting of halogen, a substituted or unsubstituted C_1 - C_6 alkyl, a substituted or unsubstituted C_1 - C_6 haloalkyl and a substituted or unsubstituted C_3 - C_6 cycloalkyl; or

when m is 2 or 3, each R^2 is independently selected from the group consisting of halogen, a substituted or unsubstituted C_1 - C_6 alkyl, a substituted or unsubstituted C_1 - C_6 haloalkyl and a substituted or unsubstituted C_3 - C_6 cycloalkyl, or two R^2 groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C_3 - C_6 cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;

R^4 is selected from the group consisting of NO_2 , $S(O)R^6$, SO_2R^6 , halogen, cyano and an unsubstituted C_1 - C_6 haloalkyl;

R^5 is $-X^1-(Alk^1)_n-R^7$;

Alk¹ is selected from an unsubstituted C₁-C₄ alkylene and a C₁-C₄ alkylene substituted with 1, 2 or 3 substituents independently selected from fluoro, chloro, an unsubstituted C₁-C₃ alkyl and an unsubstituted C₁-C₃ haloalkyl;

R⁶ is selected from the group consisting of a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl and a substituted or unsubstituted C₃-C₆ cycloalkyl;

R⁷ is selected from a substituted or unsubstituted C₁-C₆ alkoxy, a substituted or unsubstituted C₃-C₁₀ cycloalkyl, a substituted or unsubstituted 3 to 10 membered heterocyclyl, hydroxy, amino, a substituted or unsubstituted mono-substituted amine group, a substituted or unsubstituted di-substituted amine group, a substituted or unsubstituted N-carbamyl, a substituted or unsubstituted C-amido and a substituted or unsubstituted N-amido;


m is 0, 1, 2 or 3;

n is selected from the group consisting of 0 and 1; and


X¹ is selected from the group consisting of -O-, -S- and -NH-; and

the one or more of Compound (B) is a WEE1 inhibitor, or a pharmaceutically acceptable salt thereof;


wherein the WEE1 inhibitor is selected from the group consisting of



(AZD1775), NUV-569, IMP7068, Debio 0123,















(SC0191) and















(PD0166285), or a pharmaceutically acceptable salt of any of the foregoing.







2. The use of Claim 1, wherein the Compound (A) is selected from the group consisting of:
















































, and



, or a

pharmaceutically acceptable salt of any of the foregoing.

3. The use of Claim 1 or 2, wherein the WEE1 inhibitor is




, or a pharmaceutically acceptable salt thereof.

4. The use of Claim 1 or 2, wherein the WEE1 inhibitor is NUV-569, or a pharmaceutically acceptable salt thereof.

5. The use of Claim 1 or 2, wherein the WEE1 inhibitor is IMP7068, or a pharmaceutically acceptable salt thereof.


6. The use of Claim 1 or 2, wherein the WEE1 inhibitor is Debio 0123, or a pharmaceutically acceptable salt thereof.

7. The use of Claim 1 or 2, wherein the WEE1 inhibitor is



, or a pharmaceutically acceptable salt thereof.

8. The use of Claim 1 or 2, wherein the WEE1 inhibitor is



, or a pharmaceutically acceptable salt thereof.

9. The use of any one of Claims 1-8, wherein the disease or condition is a hematological malignancy.

10. The use of Claim 9, wherein the hematological malignancy is acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML).
11. The use of Claim 9, wherein the hematological malignancy is non-Hodgkin's lymphoma.
12. The use of Claim 9, wherein the hematological malignancy is Multiple Myeloma and blastic plasmacytoid dendritic cell neoplasm.
13. The use of any one of Claims 1-8, wherein the disease or condition is a solid tumor.
14. The use of Claim 13, wherein the disease or condition is selected from the group consisting of a bladder cancer, a brain cancer, a breast cancer, a cervical cancer, a choriocarcinoma, a cervicocerebral cancer, a colon cancer, an endometrial cancer, an esophageal cancer, a gallbladder/bile duct cancer, a head and neck cancer (including oral cancer), a hepatocellular cancer, a lung cancer, a non-small cell cancer, a mesothelioma, an ovarian cancer, an osteosarcoma, a pancreatic cancer, a penis cancer, an anal cancer, a prostate cancer, a testicular cancer, a small cell cancer, a small cell lung cancer, a stomach cancer, a rectal cancer, a renal pelvis/ureter cancer, a skin cancer, a soft tissue sarcoma, a stomach cancer, a testicular cancer, a thyroid cancer, an uterus body cancer and an uterocervical cancer.
15. The use of Claim 14, wherein the disease or condition is a breast cancer.
16. The use of Claim 14, wherein the disease or condition is small cell lung cancer.
17. The use of Claim 14, wherein the disease or condition is pancreatic cancer.